Cargando…

Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0

PURPOSE: Investigate in patients with metastatic and/or irresectable colorectal cancer treated with systemic treatment with capecitabine or TAS-102 whether: 1. Intestinal microbiota composition can act as a predictor for response. 2. Intestinal microbiota composition changes during systemic treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Aarnoutse, R., de Vos-Geelen, J. M. P. G. M., Penders, J., Boerma, E. G., Warmerdam, F. A. R. M., Goorts, B., Olde Damink, S. W. M., Soons, Z., Rensen, S. S. M., Smidt, M. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486633/
https://www.ncbi.nlm.nih.gov/pubmed/28444508
http://dx.doi.org/10.1007/s00384-017-2819-3
_version_ 1783246295642669056
author Aarnoutse, R.
de Vos-Geelen, J. M. P. G. M.
Penders, J.
Boerma, E. G.
Warmerdam, F. A. R. M.
Goorts, B.
Olde Damink, S. W. M.
Soons, Z.
Rensen, S. S. M.
Smidt, M. L.
author_facet Aarnoutse, R.
de Vos-Geelen, J. M. P. G. M.
Penders, J.
Boerma, E. G.
Warmerdam, F. A. R. M.
Goorts, B.
Olde Damink, S. W. M.
Soons, Z.
Rensen, S. S. M.
Smidt, M. L.
author_sort Aarnoutse, R.
collection PubMed
description PURPOSE: Investigate in patients with metastatic and/or irresectable colorectal cancer treated with systemic treatment with capecitabine or TAS-102 whether: 1. Intestinal microbiota composition can act as a predictor for response. 2. Intestinal microbiota composition changes during systemic treatment and its relation to chemotoxicity. BACKGROUND: Gut microbiota and host determinants evolve in symbiotic and dependent relationships resulting in a personal ecosystem. In vitro studies showed prolonged and increased response to 5-fluorouracil, a fluoropyrimidine, in the presence of a favorable microbiota composition. Capecitabine and TAS-102 are both fluoropyrimidines used for systemic treatment in colorectal cancer patients. METHODS: An explorative prospective multicenter cohort study in the Maastricht University Medical Centre+ and Zuyderland Medical Centre will be performed in 66 patients. Before, during, and after three cycles of systemic treatment with capecitabine or TAS-102, fecal samples and questionnaires (concerning compliance and chemotoxicity) will be collected. The response will be measured by CT/MRI using RECIST-criteria. Fecal microbiota composition will be analyzed with 16S rRNA next-generation sequencing. The absolute bacterial abundance will be assessed with quantitative polymerase chain reaction. Multivariate analysis will be used for statistical analysis. CONCLUSIONS: We aim to detect a microbiota composition that predicts if patients with metastatic and/or irresectable colorectal cancer will respond to systemic treatment and/or experience zero to limited chemotoxicity. If we are able to identify a favorable microbiota composition, fecal microbiota transplantation might be the low-burden alternative to chemotherapy switch in the future.
format Online
Article
Text
id pubmed-5486633
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-54866332017-07-11 Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0 Aarnoutse, R. de Vos-Geelen, J. M. P. G. M. Penders, J. Boerma, E. G. Warmerdam, F. A. R. M. Goorts, B. Olde Damink, S. W. M. Soons, Z. Rensen, S. S. M. Smidt, M. L. Int J Colorectal Dis Clinical Study Protocol PURPOSE: Investigate in patients with metastatic and/or irresectable colorectal cancer treated with systemic treatment with capecitabine or TAS-102 whether: 1. Intestinal microbiota composition can act as a predictor for response. 2. Intestinal microbiota composition changes during systemic treatment and its relation to chemotoxicity. BACKGROUND: Gut microbiota and host determinants evolve in symbiotic and dependent relationships resulting in a personal ecosystem. In vitro studies showed prolonged and increased response to 5-fluorouracil, a fluoropyrimidine, in the presence of a favorable microbiota composition. Capecitabine and TAS-102 are both fluoropyrimidines used for systemic treatment in colorectal cancer patients. METHODS: An explorative prospective multicenter cohort study in the Maastricht University Medical Centre+ and Zuyderland Medical Centre will be performed in 66 patients. Before, during, and after three cycles of systemic treatment with capecitabine or TAS-102, fecal samples and questionnaires (concerning compliance and chemotoxicity) will be collected. The response will be measured by CT/MRI using RECIST-criteria. Fecal microbiota composition will be analyzed with 16S rRNA next-generation sequencing. The absolute bacterial abundance will be assessed with quantitative polymerase chain reaction. Multivariate analysis will be used for statistical analysis. CONCLUSIONS: We aim to detect a microbiota composition that predicts if patients with metastatic and/or irresectable colorectal cancer will respond to systemic treatment and/or experience zero to limited chemotoxicity. If we are able to identify a favorable microbiota composition, fecal microbiota transplantation might be the low-burden alternative to chemotherapy switch in the future. Springer Berlin Heidelberg 2017-04-25 2017 /pmc/articles/PMC5486633/ /pubmed/28444508 http://dx.doi.org/10.1007/s00384-017-2819-3 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Clinical Study Protocol
Aarnoutse, R.
de Vos-Geelen, J. M. P. G. M.
Penders, J.
Boerma, E. G.
Warmerdam, F. A. R. M.
Goorts, B.
Olde Damink, S. W. M.
Soons, Z.
Rensen, S. S. M.
Smidt, M. L.
Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0
title Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0
title_full Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0
title_fullStr Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0
title_full_unstemmed Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0
title_short Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0
title_sort study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0
topic Clinical Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486633/
https://www.ncbi.nlm.nih.gov/pubmed/28444508
http://dx.doi.org/10.1007/s00384-017-2819-3
work_keys_str_mv AT aarnoutser studyprotocolontheroleofintestinalmicrobiotaincolorectalcancertreatmentapathwaytopersonalizedmedicine20
AT devosgeelenjmpgm studyprotocolontheroleofintestinalmicrobiotaincolorectalcancertreatmentapathwaytopersonalizedmedicine20
AT pendersj studyprotocolontheroleofintestinalmicrobiotaincolorectalcancertreatmentapathwaytopersonalizedmedicine20
AT boermaeg studyprotocolontheroleofintestinalmicrobiotaincolorectalcancertreatmentapathwaytopersonalizedmedicine20
AT warmerdamfarm studyprotocolontheroleofintestinalmicrobiotaincolorectalcancertreatmentapathwaytopersonalizedmedicine20
AT goortsb studyprotocolontheroleofintestinalmicrobiotaincolorectalcancertreatmentapathwaytopersonalizedmedicine20
AT oldedaminkswm studyprotocolontheroleofintestinalmicrobiotaincolorectalcancertreatmentapathwaytopersonalizedmedicine20
AT soonsz studyprotocolontheroleofintestinalmicrobiotaincolorectalcancertreatmentapathwaytopersonalizedmedicine20
AT rensenssm studyprotocolontheroleofintestinalmicrobiotaincolorectalcancertreatmentapathwaytopersonalizedmedicine20
AT smidtml studyprotocolontheroleofintestinalmicrobiotaincolorectalcancertreatmentapathwaytopersonalizedmedicine20